Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Approval sought for exemestane tablets as therapy for postmenopausal women
December 28th, 2004
Pfizer announced on December 8, 2004, that it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Aromasin (exemestane tablets) in the adjuvant treatment of postmenopausal women with estrogen-receptor (ER+) positive or receptor-unknown early-stage breast cancer. Aromasin is a hormonal therapy that belongs to a class of drugs called aromatase inhibitors, which work by blocking the production of estrogen. Estrogen is known to play a key role in the development and growth of breast cancer. For many years, treatment with tamoxifen has been the standard hormonal therapy for...
Source: Cancer Weekly (2004-12-28)
|
